OS Therapies announced alignment with the FDA on the adaptive design for its Phase 3 clinical trial for OST-HER2, expected to start in Q4 2026. Concurrently, the UK's MHRA will represent the company in Project Orbis, a global initiative to accelerate oncology drug approvals, potentially streamlining regulatory processes in multiple regions.
OS Therapies has achieved significant regulatory milestones for its OST-HER2 therapy. The FDA's alignment on the Phase 3 trial design, coupled with MHRA's commitment to lead the company's Project Orbis participation, significantly de-risks the regulatory pathway for OST-HER2. This could lead to faster market access in the US, UK, and Europe, benefiting OS Therapies. The potential for a Priority Review Voucher (PRV) worth hundreds of millions of dollars upon BLA approval further adds to the company's financial prospects. This news is a positive catalyst for OS Therapies, indicating progress towards commercialization and potential revenue generation, though the Phase 3 trial is still years away from completion.